Revumenib + Mao Inhibitors Interaction
Moderateinteraction on record
Description
Concomitant use increases revumenib systemic exposure, which may increase the risk of adverse reactions. Dose reduction of REVUFORJ is required.
Mechanism
Strong CYP3A4 inhibitors reduce metabolism of revumenib, which is primarily metabolized by CYP3A4
Source: NLP:revumenib